The new research on hepatitis C involved three separate laboratory groups at The Scripps Research Institute. Shown here are key team members (left to right) Andrew Ward, Ian Wilson, Leopold Kong and Mansun Law.
Scientists at the Scripps Research Institute (TSRI) have determined the most detailed picture yet of a crucial part of the hepatitis C virus, which the virus uses to infect liver cells. The new data reveal unexpected structural features of this protein and should greatly speed efforts to make an effective hepatitis C vaccine. The findings, which appear in the November 29, 2013 issue of the journal Science, focus on a protein known as E2 envelope glycoprotein.
Were excited by this development, says Ian A. Wilson, the Hansen Professor of Structural Biology at TSRI and a senior author of the new research with TSRI assistant professors Mansun Law and Andrew B. Ward. It has been very hard to get a high resolution structure of E2 and it took years of painstaking work to finally accomplish that.
Any successful hepatitis C vaccine is likely to target the E2 protein. Scientists already have isolated rare antibodies from patients that can bind E2 in ways that neutralize a broad range of viral strains.
It took our team six years to crack this very difficult scientific problem, but we didnt give up, says Law. Now that we can visualize the structural details of these binding sites, we can design vaccine molecules that mimic them.
There has long been an urgent need for an effective vaccine against hepatitis C virus. Once confined to isolated geographical regions, the virus spread globally during the 20th century, chiefly via blood transfusions, unsterilized medical instruments and re-used hypodermic needles. Although hospitals have screened blood products for hepatitis C virus (HCV) since the early 1990s, as many as 200 million people currently are thought to harbor the virus. These include more than 3 million people in the United States, where the virus is responsible for more deaths each year than HIV.
HCV was able to spread so widely because it typically causes few or no symptoms when it infects someone. In many cases it establishes a long-term infection of the liver, damaging it slowly for decadesuntil liver cirrhosis and/or cancer develop. Its known as a silent killer, says Law. Expensive and risky liver transplantation is often the only way to save a patients life. Some antiviral drugs are useful in treating and even curing chronic HCV infection, but the more effective ones are extremely expensiveand most HCV-positive people dont even know that theyre infected and need treatment.
An HCV vaccine could put an end to the global pandemic by preventing new infections. It could be given to people when theyre young and healthy, and theyd never have to worry about developing HCV-related liver diseases, says Ward.
However, like HIV and some other viruses, HCV uses several effective countermeasures to evade the immune system. These include fast-mutating regions on the E2 protein, which ensure that antibodies to one HCV strain typically are ineffective against other strains. The E2 protein also coats itself with relatively antibody-proof sugar molecules.
To defeat these viral countermeasures, scientists have wanted to see the high-resolution atomic structure of HCV, particularly E2 and its CD81 receptor binding site, which does not vary much from strain to strain. In recent years, Laws laboratory and others have isolated antibodies that manage to grab hold of this relatively conserved region of E2, thereby blocking the infectivity of a large fraction of HCV strains. In principle, a vaccine that prompts the body to make similar antibodies would effectively and cheaply immunize people against most of their risk of HCV infection.
But precisely mimicking these antibody-binding sites in a vaccine means first determining their high-resolution structures, which has been difficult even to attempt. Usually if you try to express the E2 protein in cultured cells, you either cant express it in useful quantities or you can but it aggregates and becomes a big mess, says Leopold Kong, a research associate in the Wilson laboratory who was the studys lead author.
Over the past several years, Kong and his colleagues have run dozens of experiments to find the right way to modify E2enough that the protein doesnt aggregate so readily and also so that the antibody-binding sites are maintained. This would enable the protein to be soluble and pure enough to grow crystals to determine its structure by the technique known as X-ray crystallography. It was a Herculean effort, says Ward. This is one of the most difficult and unstable viral envelope proteins around.
In the end, the team succeeded, using a slightly altered version of E2the E2 corewith some of its glycans (sugar molecules) and outer variable and stalk segments removed. The scientists were then able to obtain the high-resolution structure of the protein while it was bound to a known broadly neutralizing antibody developed at TSRI. The scientists then followed up by imaging a more complete version of E2 using electron microscopy to extend the structural model.
When finally revealed, E2s structure surprised the researchers. It had been thought that HCVs E2 belongs to a family of viral fusion proteins called class 2 fusion proteins, which includes envelope proteins for West Nile and dengue viruses, for example, says Kong. But we showed that E2 is structurally distinct and probably works differently than what had been widely assumed.
Based on the new structural data, Law and colleagues at TSRI are already designing and testing novel antibody-stimulating components of a future HCV vaccine. Having the E2 structure has certainly helped us, says Law.
Other co-authors of the study, Hepatitis C virus E2 envelope glycoprotein core structure, were Erick Giang and Kristin E. Cogburn of the Law lab at TSRI; Robyn L. Stanfield, Rameshwar U. Kadam, Yuanzi Hua and Xiaoping Dai of the Wilson lab; Travis Nieusma of the Ward lab; and Professor Dennis Burton of TSRIs Department of Immunology and Microbial Science.
The study was funded in part by the National Institutes of Health (AI079031, AI080916, AI071084, AI084817, U54 GM094586 and RR017573) and the Skaggs Institute of Chemical Biology at TSRI.
Source: Scripps Research Institute